Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 2 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ventus Therapeutics U S Inc. currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This level of activity indicates a concentrated effort to secure patent protection for their biological or pharmaceutical assets. The presence of 4 actions suggests multiple applications are moving through the examination process at the same time.
These 4 pending office actions are being reviewed by 2 distinct examiners across 2 distinct art units. This concentration is notable because it means each examiner is handling multiple cases for the company. Specifically, the ratio of 4 actions to 2 examiners implies that the technical subject matter is consistent enough to be grouped under the same reviewers and art units.
RAHMANI, NILOOFAR is the busiest examiner for the portfolio, with 2 busiest examiner pending actions currently assigned. This individual manages a portion of the company's total pending workload. Because the 4 pending office actions are concentrated among only 2 distinct examiners, the company can develop a specialized strategy tailored to the specific preferences of these individuals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 2 | 77.6% | -2.9% |
| ARCORIA, PAUL JOSEPH | 2 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18544945 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706884 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18936409 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | RAHMANI, NILOOFAR | — | §112Other | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18891602 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | RAHMANI, NILOOFAR | 1691 | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18706884 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §102§103§112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18544945 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103DP | Non-Final OA | — | Pending | Dec 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVentus Therapeutics U S Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Niloofar Rahmani has the most, with 2 of Ventus Therapeutics U S Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
